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Donald McDonald
University of California, San Francisco
It is much easier to describe the perfect person
to be director of the National Cancer Institute
(NCI) than to find him or her. That person
would need to balance the needs, hopes and
challenges of state-of-the-art clinical oncolo-
gists with those of basic scientists. The ideal
candidate must understand the inner workings
of the NCI as the pace-setting institute that it is,
but also as one of 27 separate institutes and cen-
tres — with competing identities, missions and
needs — that make up the National Institutes of
Health (NIH). Also, this person will have to
address the challenges faced by cancer research,
like all biomedical research, with declining
funding and the changing political climate.  
One approach would be to look for some-
one within the NIH — someone who recog-
nizes all of these problems yet is not daunted
by the financial and political conditions. An
example would be the current NCI deputy
director, John Niederhuber.
Bert Vogelstein
Johns Hopkins University School of
Medicine, Baltimore, Maryland
I would suggest Bill Gates as the new director,
for two reasons. First, he is one of the few people
who could make up shortfalls in funding. Sec-
ond, and more seriously, he would bring a busi-
ness perspective that is sorely needed. The NCI
is riddled with old programmes that are viewed
almost as entitlements and have hindered past
directors from realizing their visions. These ves-
tiges of the past drastically limit the agency’s
ability to support novel initiatives and, most
importantly, new investigators. Just as a business
evaluates each of its products in an effort to
maximize profits, each NCI programme should
be subjected to a “zero-based budgeting” analy-
sis based on scientific or clinical productivity
and the likely impact on disease. 
Mary-Claire King 
University of Washington, Seattle 
In my view, the next NCI director should have
direct experience of NCI-funded, extramural
research in his or her own lab; experience 
of translating research into patient care; and
knowledge of how the NIH and NCI work. I
would begin my list with the current directors
of the 39 NCI-designated Comprehensive
Cancer Centers. These people are respected,
and have worked for cancer patients and
researchers for their entire careers. 
Waun Ki Hong
University of Texas M. D. Anderson
Cancer Center, Houston
The NCI director must have a strong track
record as a cancer researcher. This person
needs a really strong vision and passion for
cancer research. She or he must be an excellent
advocate with keen political skills. And they
must be highly respected and recognized by
their peers in the cancer community. With
these qualities in mind, I think any of the fol-
lowing people would make a fine director:
Phillip Sharp of the Massachusetts Institute of
Technology; Max Wicha of the University of
Michigan; Harold Moses at the Vanderbilt-
Ingram Cancer Center; and Martin Abeloff at
Johns Hopkins University.
Hellmut Augustin
University of Freiburg, Germany
Commenting on an American issue from a
European perspective is like interfering in
domestic affairs — usually not well appreci-
ated. On second thoughts, it is quite tempting.
It should be a strong personality who is well
rooted in basic as well as translational oncol-
ogy research, a scientist with a vision beyond
the tumour-cell-centric view, and probably
(but not necessarily) an MD or an MD/PhD.
The job needs someone from outside who can
motivate and develop a new corporate identity
at the agency, a person of the highest degree of
scientific integrity, and an efficient adminis-
trator with excellent communication skills.
The first person who comes to mind who
would fulfil such criteria is Carl-Henrik
Heldin at the Ludwig Institute for Cancer
Research in Uppsala, Sweden. But why not a
female scientist? Margaret Kripke of M. D.
Anderson is a member of the President’s 
Cancer Panel. How about a strong basic scien-
tist with an industry background, such as
Mark Fishman of the Novartis Institutes for
THE NCI
AT A GLANCE
Location: Bethesda, Maryland, with a satellite
facility in nearby Frederick.
Budget: $4.8 billion annually, making it the
largest institute in the National Institutes of
Health.
Purpose: Among many others, to conduct
leading research into the causes and treatment
of cancer. Andrew von Eschenbach, NCI’s
outgoing head, has set a goal to eliminate
suffering and death from cancer by 2015. 
Many researchers see this as unrealistic.
The White House is looking for a new head for the National 
Cancer Institute. What kind of person does it take to run a 
$4.8-billion research powerhouse? Nature asked some top 
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BioMedical Research? Or a bona fide cancer
researcher: Bert Vogelstein, Doug Hanahan,
Robert Weinberg of the Whitehead Institute
or…? Well, a European should probably not
interfere in domestic affairs!
Douglas Hanahan
University of California, San Francisco
I would choose Harold Varmus, currently
president of the Memorial Sloan-Kettering
Cancer Center. Thirty years of cutting-edge
research have given Varmus a deep under-
standing of the biology and genetics of cancer.
Formerly director of the NIH, he knows about
leading a major government agency. Now, as
president of Sloan-Kettering, he has assembled
an impressive team in basic, translational and
clinical cancer research and cancer care, and
has recruited world-class scientists and physi-
cians to his institution. This combination of
research excellence, grounding in medicine
and experience in relevant institutional 
leadership has uniquely prepared Varmus 
to guide the NCI and the cancer research 
community.
Marc Lippman
University of Michigan School of
Medicine, Ann Arbor
I think the ideal candidate should be seen by
scientists and others in the field as scholarly,
original in their thinking, and able to capture
the enthusiasm and involvement of the many
diverse constituencies that make up the com-
munity of people who dedicate their lives to
eradicating cancer. Here is an eclectic set of
names who I think meet all of those criteria:
Mina Bissell of the Lawrence Berkeley National
Laboratory; Isaiah Fidler of the University of
Texas M. D. Anderson Cancer Center; Larry
Norton of Memorial Sloan-Kettering Cancer
Center; and Philip Pizzo of Stanford University.
Interviews by Jacqueline Ruttimann and
Meredith Wadman
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